Skip to main content

Turn any podcast RSS feed into searchable transcripts, summaries, and episode chat.

No card • 10 free transcript credits
Sign up free with Google
No Priors: Artificial Intelligence | Technology | Startups
Virtual Cell Models, Tahoe-100 and Data for AI-in-Bio with Vevo Therapeutics and the Arc Institute
No Priors: Artificial Intelligence | Technology | Startups

Virtual Cell Models, Tahoe-100 and Data for AI-in-Bio with Vevo Therapeutics and the Arc Institute

Conviction 57m 14 months ago
At this moment of inflection in technology, co-hosts Elad Gil and Sarah Guo talk to the world's leading AI engineers, researchers and founders about the biggest questions: How far away is AGI? What markets are at risk for disruption? How will commerce, culture, and society change? What’s happening in state-of-the-art in research? “No Priors” is your guide to the AI revolution. Email feedback to show@no-priors.com. Sarah Guo is a startup investor and the founder of Conviction, an investment firm purpose-built to serve intelligent software, or "Software 3.0" companies. She spent nearly a decade incubating and investing at venture firm Greylock Partners. Elad Gil is a serial entrepreneur and a startup investor. He was co-founder of Color Health, Mixer Labs (which was acquired by Twitter). He has invested in over 40 companies now worth $1B or more each, and is also author of the High Growth Handbook.

Show Notes

Tap timecodes to jump
On this week’s episode of No Priors, Sarah Guo is joined by leading members of the teams at Vevo Therapeutics and the Arc Institute – Nima Alidoust, CEO/Co-Founder at Vevo Therapeutics; Johnny Yu, CSO/Co-Founder at Vevo Therapeutics; Patrick Hsu, CEO/Co-Founder at Arc Institute; Dave Burke, CTO at Arc Institute; and Hani Goodarzi, Core Investigator at Arc Institute. Predicting protein structure (AlphaFold 3, Chai-1, Evo 2) was a big AI/biology breakthrough. The next big leap is modeling entire human cells—how they behave in disease, or how they respond to new therapeutics. The same way LLMs needed enormous text corpora to become truly powerful, Virtual Cell Models need massive, high-quality cellular datasets to train on. In this episode, the teams discuss the groundbreaking release of the Tahoe-100M single cell dataset, Arc Atlas, and how these advancements could transform drug discovery.
Sign up for new podcasts every week. Email feedback to show@no-priors.com
Follow us on Twitter: @NoPriorsPod | @Saranormous | @Nalidoust | @IAmJohnnyYu | @PDHsh | @Davey_Burke | @Genophoria
Download the Tahoe Dataset
Show Notes:
Introduction
Significance of Tahoe-100M dataset
Where we are with virtual cell models and protein language models
Significance of perturbational data
Challenges and innovations in data collection
Open sourcing and community collaboration
Predictive ability and importance of virtual cell models
Drug discovery and virtual cell models
Platform vs. single hypothesis companies
Rise of Chinese biotechs
AI in drug discovery

Transcript not yet processed.

Sign in to unlock (1 credit)

Full transcripts, AI insights,
episode chat — free.

Sign up with Google in one click. 10 unlock credits included. No card needed.

Google sign-in · No credit card · Cancel anytime